Hamlin Capital Management LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 12.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,324,078 shares of the biopharmaceutical company’s stock after selling 325,229 shares during the period. Pfizer comprises approximately 4.7% of Hamlin Capital Management LLC’s holdings, making the stock its 2nd largest position. Hamlin Capital Management LLC’s holdings in Pfizer were worth $101,446,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Strategic Family Wealth Counselors L.L.C. purchased a new position in Pfizer during the fourth quarter valued at approximately $7,665,000. Diversified Trust Co grew its position in Pfizer by 30.1% in the fourth quarter. Diversified Trust Co now owns 30,599 shares of the biopharmaceutical company’s stock worth $1,336,000 after acquiring an additional 7,071 shares in the last quarter. R.H. Dinel Investment Counsel Inc. bought a new stake in Pfizer in the fourth quarter worth approximately $705,000. Weather Gauge Advisory LLC bought a new stake in Pfizer in the fourth quarter worth approximately $1,959,000. Finally, First American Bank grew its position in Pfizer by 5.4% in the fourth quarter. First American Bank now owns 192,312 shares of the biopharmaceutical company’s stock worth $8,395,000 after acquiring an additional 9,910 shares in the last quarter. 69.53% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms have commented on PFE. Credit Suisse Group reissued a “neutral” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, January 28th. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, April 10th. Bank of America boosted their target price on shares of Pfizer from $45.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. ValuEngine downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Finally, Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a research report on Thursday, January 31st. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $45.61.
NYSE PFE opened at $42.09 on Tuesday. The company has a quick ratio of 1.33, a current ratio of 1.57 and a debt-to-equity ratio of 0.52. The firm has a market cap of $248.41 billion, a P/E ratio of 14.03, a PEG ratio of 2.55 and a beta of 0.75. Pfizer Inc. has a 1 year low of $34.37 and a 1 year high of $46.47.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.01. The business had revenue of $13.98 billion during the quarter, compared to the consensus estimate of $13.92 billion. Pfizer had a net margin of 20.79% and a return on equity of 26.02%. Pfizer’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.62 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.86 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This story was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.chaffeybreeze.com/2019/04/16/pfizer-inc-pfe-position-reduced-by-hamlin-capital-management-llc.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
See Also: Diversification in Your Portfolio
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.